Summary

The IMPROVE-IT trial showed that the cholesterol-lowering drug ezetimibe, when added to simvastatin, provides greater improvement in cardiovascular outcomes among patients with diabetes vs those without diabetes in a population with acute coronary syndrome. Additionally, the rate of new-onset diabetes was not increased among patients treated with ezetimibe.